Oxford Biomedica PLC

Board/Management Information • Jul 2, 2025

National Storage Mechanism | Additional information

RNS Number : 3814P

Oxford Biomedica PLC

02 July 2025

OXB Directorship notification under UK Listing Rule 6.4.9R(2)

Oxford, UK - 2 July 2025:  OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that Mr. Colin Bond, Independent Non-Executive Director, has been appointed as Additional Director (Non-Executive, Independent) of OneSource Specialty Pharma Limited, a company listed at the National Stock Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE), subject to the approval of the shareholders by way of special resolution expected to be announced on or around 1 August 2025 .

-Ends-

Enquiries:       

OXB

Natalie Walter, Company Secretary - T : +44 (0) 1865 783 000 / E: cosec@oxb.com

About OXB

OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early - stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the Tetra V ecta™ system), a dual - plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.

OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and Bedford MA, US. Learn more at www.oxb.com , and follow us on LinkedIn and YouTube.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RDNRTMATMTIMMRA